HANXBIO-B (03378.HK): Ties Up with Ditu Zhiyuan on BioAI Platform

On 16 November 2026, HANXBIO-B (03378.HK) said it signed a research agreement with Suzhou Ditu Zhiyuan to use its Meritudio BioAI platform for cancer R&D.

NewTimeSpace News: On 16 November 2026, Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (stock code: 03378) announced that it formally entered into a research cooperation agreement with Suzhou Ditu Zhiyuan Biotechnology Co., Ltd. on 11 November 2026.

The two parties will use the Meritudio BioAI cloud platform independently developed by Ditu Zhiyuan to conduct translational and clinical medical research on Hanx Biopharmaceuticals' proprietary innovative oncology pipeline. By combining artificial intelligence, multi-omics bioinformatics and clinical big data analysis, the collaboration will provide big data support and AI guidance for preclinical and translational research plans and clinical development strategies.

Ditu Zhiyuan, based in the Suzhou Industrial Park, provides R&D services and software to the biopharma industry; its Meritudio BioAI platform consolidates data scattered across experiments, clinical work and literature into a basis for project evaluation, mechanism-of-action studies and clinical development decisions. Hanx Biopharmaceuticals, founded in 2014, focuses on structural biology, translational medicine and clinical development for next-generation immunotherapies. The announcement carries the Rule 18A.05 warning that the relevant products may not ultimately be successfully developed and marketed.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.